Shandong Lukang Pharmaceutical (SHA:600789) received approval from China's National Medical Products Administration for the marketing of lenvatinib mesylate as a chemical active pharmaceutical ingredient, according to a Shanghai bourse filing on Thursday.
The drug is used as a treatment for patients with unresectable hepatocellular carcinoma who have not previously received systemic therapy.
The Chinese pharmaceutical company's shares rose 2% during the afternoon trade.